Top-Rated StocksTop-RatedNASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free arvn Stock Alerts $31.44 -0.51 (-1.60%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$31.25▼$32.4250-Day Range$31.60▼$47.6752-Week Range$13.57▼$53.08Volume567,898 shsAverage Volume718,173 shsMarket Capitalization$2.15 billionP/E RatioN/ADividend YieldN/APrice Target$61.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arvinas alerts: Email Address Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside94.4% Upside$61.13 Price TargetShort InterestBearish12.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 24 Articles This WeekInsider TradingSelling Shares$404,489 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.02) to ($4.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector396th out of 915 stocksPharmaceutical Preparations Industry182nd out of 426 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.68% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently decreased by 3.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.8 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Arvinas this week, compared to 3 articles on an average week.Search Interest3 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $404,489.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($5.02) to ($4.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesMay 10, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Rating Reiterated by WedbushMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Arvinas (NASDAQ:ARVN)May 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).May 10, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Price Target Cut to $68.00May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Arvinas with Promising Trial Updates and Robust Financial OutlookMay 9, 2024 | globenewswire.comArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressMay 8, 2024 | markets.businessinsider.comStrong Buy Recommendation for Arvinas Holding Company on Innovative Pipeline and Strategic PartnershipsMay 8, 2024 | finance.yahoo.comWe Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business GrowthMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).May 7, 2024 | investorplace.comARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comArvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | theglobeandmail.comAs Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponseApril 26, 2024 | investing.comArvinas appoints new chief business officerApril 26, 2024 | finanznachrichten.deArvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 24, 2024 | globenewswire.comArvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerApril 20, 2024 | finance.yahoo.comArvinas, Inc. (ARVN)April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth PotentialApril 11, 2024 | investors.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 11, 2024 | markets.businessinsider.comArvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock JumpsApril 11, 2024 | globenewswire.comArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerMarch 20, 2024 | seekingalpha.comArvinas gets new chief medical officerMarch 19, 2024 | msn.comArvinas gets new chief medical headMarch 18, 2024 | globenewswire.comArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerMarch 4, 2024 | globenewswire.comArvinas to Participate in Upcoming Investor ConferencesMarch 3, 2024 | seekingalpha.comArvinas: Behind The Huge RallyMarch 1, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?February 28, 2024 | markets.businessinsider.comArvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease TreatmentSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees445Year FoundedN/APrice Target and Rating Average Stock Price Target$61.13 High Stock Price Target$90.00 Low Stock Price Target$20.00 Potential Upside/Downside+94.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net Margins-185.09% Pretax Margin-463.57% Return on Equity-70.24% Return on Assets-31.79% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$71.30 million Price / Sales30.12 Cash FlowN/A Price / Cash FlowN/A Book Value$11.99 per share Price / Book2.62Miscellaneous Outstanding Shares68,308,000Free Float64,735,000Market Cap$2.15 billion OptionableOptionable Beta1.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 64)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 61)Chief Scientific Officer Comp: $692kDr. Randy Teel Ph.D. (Age 44)Interim CFO & Treasurer Mr. David K. Loomis M.B.A. (Age 50)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsMr. Jared M. Freedberg J.D. (Age 55)General Counsel & Corporate Secretary Mr. Steve Weiss (Age 54)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 67)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 56)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 46)Chief Commercial Officer More ExecutivesKey CompetitorsGeronNASDAQ:GERNDyne TherapeuticsNASDAQ:DYNRhythm PharmaceuticalsNASDAQ:RYTMAvidity BiosciencesNASDAQ:RNAMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemBought 2,590 shares on 5/9/2024Ownership: 0.024%ProShare Advisors LLCBought 2,188 shares on 5/8/2024Ownership: 0.020%Russell Investments Group Ltd.Sold 5,282 shares on 5/8/2024Ownership: 0.007%Swiss National BankBought 24,600 shares on 5/7/2024Ownership: 0.167%Sei Investments Co.Bought 16,831 shares on 5/7/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price target for 2024? 16 equities research analysts have issued twelve-month price targets for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's share price to reach $61.13 in the next twelve months. This suggests a possible upside of 94.4% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2024? Arvinas' stock was trading at $41.16 at the beginning of the year. Since then, ARVN stock has decreased by 23.6% and is now trading at $31.44. View the best growth stocks for 2024 here. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($1.42) by $0.45. The firm earned $25.30 million during the quarter, compared to the consensus estimate of $32.94 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. The company's revenue was down 22.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.54) earnings per share. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), iShares U.S. Pharmaceuticals ETF (IHE), Harbor Disruptive Innovation ETF (INNO) and Zacks Small/Mid Cap Core Portfolio ETF (SMIZ).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nordea Investment Management AB (0.40%), Wasatch Advisors LP (0.30%), BNP Paribas Financial Markets (0.22%), Swiss National Bank (0.17%), Hennion & Walsh Asset Management Inc. (0.09%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARVN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.